2. Academic Validation
  3. Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A

Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A

  • J Med Chem. 2021 Nov 11;64(21):15883-15911. doi: 10.1021/acs.jmedchem.1c01245.
Lars Wortmann 1,  Nico Bräuer 1,  Simon J Holton 1,  Horst Irlbacher 1,  Jörg Weiske 1,  Christian Lechner 1,  Robin Meier 1,  Jakob Karén 2,  Catrine Berthold Siöberg 2,  Vera Pütter 1,  Clara D Christ 1,  Antonius Ter Laak 1,  Philip Lienau 1,  Ralf Lesche 1,  Barbara Nicke 1,  Shing-Hu Cheung 1,  Marcus Bauser 1,  Andrea Haegebarth 1,  Franz von Nussbaum 1,  Dominik Mumberg 1,  Clara Lemos 1
Affiliations

Affiliations

  • 1 Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.
  • 2 Pelago Bioscience AB, Banvaktsvägen 20, 171 48 Solna, Sweden.
PMID: 34699202 DOI: 10.1021/acs.jmedchem.1c01245
Abstract

PIP4K2A is an insufficiently studied type II lipid kinase that catalyzes the conversion of phosphatidylinositol-5-phosphate (PI5P) into phosphatidylinositol 4,5-bisphosphate (PI4,5P2). The involvement of PIP4K2A/B in Cancer has been suggested, particularly in the context of p53 mutant/null tumors. PIP4K2A/B depletion has been shown to induce tumor growth inhibition, possibly due to hyperactivation of Akt and reactive oxygen species-mediated Apoptosis. Herein, we report the identification of the novel potent and highly selective inhibitors BAY-091 and BAY-297 of the kinase PIP4K2A by high-throughput screening and subsequent structure-based optimization. Cellular target engagement of BAY-091 and BAY-297 was demonstrated using cellular thermal shift assay technology. However, inhibition of PIP4K2A with BAY-091 or BAY-297 did not translate into the hypothesized mode of action and antiproliferative activity in p53-deficient tumor cells. Therefore, BAY-091 and BAY-297 serve as valuable chemical probes to study PIP4K2A signaling and its involvement in pathophysiological conditions such as Cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-139868
    99.55%, PIP4K2A激酶抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z